Last checked at 23 Jun 2020 07:00
23 June 2020
Hikma Pharmaceuticals PLC ("Hikma" or the "Company")
Transaction in Own Shares and Total Voting Rights and Capital
Further to the announcements by Hikma and Boehringer Ingelheim Invest GmbH ("Boehringer Ingelheim") on 22nd June 2020, Hikma today announces the Company has entered into arrangements to buy back approximately 12.8 million ordinary shares (the "Buy Back Shares") currently owned by Boehringer Ingelheim (the "Buy Back") at a price per Buy Back Share of £23.00 (the "Buy Back Price"). Hikma will receive a commitment fee from Boehringer Ingelheim of 2 per cent. of the aggregate value of the Buy Back Shares acquired at the Buy Back Price. Citigroup Global Markets Limited ("Citi") is acting as riskless principal for the purpose of the Buy Back.
The Buy Back Shares will all be held as treasury shares. Following the Buy Back, the Company's share capital consists of 243,283,072 ordinary shares carrying voting rights, of which 12,833,233 (5.3%) ordinary shares are held in treasury. The voting rights attaching to the treasury shares are not capable of exercise. Therefore the total number of the voting rights in the Company (after excluding the treasury shares) is 230,449,839 ("Total Voting Rights").
The Total Voting Rights figure (230,449,839) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
Citi and Goldman Sachs International ("Goldman Sachs") are acting as joint financial advisers to Hikma on the Buy Back.
Enquiries:
Hikma | |
Susan Ringdal EVP, Strategic Planning and Global Affairs | +44 (0)20 7399 2760/+44 (0)7776 477050 |
Guy FeatherstoneSenior Investor Relations Manager | +44 (0)20 3892 4389/+44 (0)7795 896738 |
Citi (Financial Adviser and Corporate Broker to Hikma) | +44 (0)20 7986 4000 |
Andrew Seaton | |
Robert Way | |
Suneel Hargunani | |
Goldman Sachs (Financial Adviser to Hikma) | +44 (0)20 7774 1000 |
Robert King | |
John Wilkinson | |
Christoph Stanger | |
Teneo (Public Relations Adviser to Hikma) | |
Charles Armitstead | +44 (0)7703 330 269 |
Camilla Cunningham | +44 (0)7464 982 426 |
About Hikma
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated Ba1/stable Moody's and BB+/positive S&P)
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
©2020 Hikma Pharmaceuticals PLC. All rights reserved.
Disclaimer
Citi, which is authorised by the Prudential Regulation Authority and regulated in the UK by the Financial Conduct Authority and the Prudential Regulation Authority is acting as financial adviser and corporate broker to Hikma and for no one else in connection with the Buy Back and other matters described in this announcement, and will not be responsible to anyone other than Hikma for providing the protections afforded to its clients nor for providing advice in relation to the Buy Back or any other matters referred to in this announcement. Neither Citi nor any of its affiliates, directors or employees owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, consequential, whether in contract, tort, in delict, under statute or otherwise) to any person who is not a client of Citi in connection with this announcement, any statement contained herein, the Buy Back or otherwise.
Goldman Sachs, which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting as financial adviser to Hikma and no one else in connection with the Buy Back and will not be responsible to anyone other than Hikma for providing the protections afforded to clients of Goldman Sachs International or for providing advice in connection with the Buy Back or in this Announcement or any transaction or arrangement referred to herein.
Further Information
This communication is not intended to and does not constitute an offer to buy or the solicitation of an offer to subscribe for or sell or an invitation to purchase or subscribe for any securities or the solicitation of any vote in any jurisdiction. The release, publication or distribution of this communication in whole or in part, directly or indirectly, in, into or from certain jurisdictions may be restricted by law and therefore persons in such jurisdictions should inform themselves about and observe such restrictions.
The distribution of this announcement in jurisdictions outside the United Kingdom may be restricted by law and therefore persons into whose possession this announcement comes should inform themselves about, and observe, such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdictions.